Karim Aly
CEO
Noze
Noze offers a silicon‑based breath analysis platform that uses nano‑sensor arrays and an AI perception engine to detect trace volatile organic compounds in exhaled air with clinical precision. The system provides real‑time, non‑invasive diagnostics through two modes—SpotLight™ for rapid single‑biomarker detection and DeepScan™ for comprehensive disease fingerprint profiling—enabling hospitals and point‑of‑care facilities to screen for cancer, infectious diseases, metabolic conditions, and respiratory inflammation without blood draws or lab delays.
- Artificial Intelligence
- Clean Technology
- Hardware
- Healthcare Technology
- Internet of Things
- Medical Devices
Updated 2 days ago
Funding
Raised to date
$5MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Current diagnostic methods often rely on invasive samples such as blood draws or swabs, require laboratory processing, and involve delays before results are available. This limits the ability to detect diseases early, monitor metabolic health continuously, and make rapid clinical decisions at the point of care.
Solution
Noze has developed a silicon-based breath analysis platform that captures and interprets the molecular composition of exhaled air in real time. The system uses nano‑sensor arrays to detect trace volatile organic compounds with clinical precision, while an AI perception engine translates these patterns into actionable health insights. Two operating modes—SpotLight™ for targeted biomarker detection and DeepScan™ for comprehensive disease fingerprint profiling—enable rapid screening for cancer, infectious diseases, metabolic conditions, and respiratory inflammation directly at the bedside or in outpatient settings. The platform is designed for semiconductor manufacturing, allowing scalable production and deployment across diverse care environments.
Target Audience
Primary customers are hospitals, clinics, and point‑of‑care facilities that require rapid, non‑invasive diagnostics, as well as research organizations developing therapeutic and wearable health solutions.
Features
- Nano‑sensor chip arrays that detect trace molecular patterns in breath with high sensitivity and specificity
- AI-driven analytics engine that converts raw sensor data into clinically validated disease signatures
- SpotLight™ mode for fast, single‑biomarker detection to support immediate decision‑making
- DeepScan™ mode for broad molecular fingerprinting to identify multiple disease states simultaneously
- Real‑time results delivery without the need for blood draws, swabs, or centralized lab processing
- Semiconductor‑compatible design enabling mass production and cost‑effective scaling
- Applications across oncology, infectious disease screening, metabolic health monitoring, critical care rule‑outs, and asthma management